Literature DB >> 22416839

Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.

Jianrong Wu1, Lorraine Tracey, Andrew M Davidoff.   

Abstract

Statistical methods for assessing the joint action of compounds administered in combination have been established for many years. However, there is little literature available on assessing the joint action of fixed-dose drug combinations in tumor xenograft experiments. Here an interaction index for fixed-dose two-drug combinations is proposed. Furthermore, a regression analysis is also discussed. Actual tumor xenograft data were analyzed to illustrate the proposed methods.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22416839      PMCID: PMC4667736          DOI: 10.1080/10543406.2011.556285

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  13 in total

1.  Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.

Authors:  Ming Tan; Hong-Bin Fang; Guo-Liang Tian; Peter J Houghton
Journal:  Stat Med       Date:  2003-07-15       Impact factor: 2.373

2.  Design and analysis of drug combination experiments.

Authors:  Roel Straetemans; Timothy O'Brien; Luc Wouters; Jacky Van Dun; Michel Janicot; Luc Bijnens; Tomasz Burzykowski; Marc Aerts
Journal:  Biom J       Date:  2005-06       Impact factor: 2.207

3.  A semiparametric response surface model for assessing drug interaction.

Authors:  Maiying Kong; J Jack Lee
Journal:  Biometrics       Date:  2007-09-26       Impact factor: 2.571

4.  Measurement of the potencies of drug mixtures.

Authors:  P S Hewlett
Journal:  Biometrics       Date:  1969-09       Impact factor: 2.571

5.  Evaluating the efficacy of a combination therapy.

Authors:  S M Snapinn
Journal:  Stat Med       Date:  1987-09       Impact factor: 2.373

Review 6.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

7.  Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials.

Authors:  H M Hung
Journal:  Stat Med       Date:  1993-04-15       Impact factor: 2.373

8.  Testing for the existence of a desirable dose combination.

Authors:  H M Hung; G Y Chi; R J Lipicky
Journal:  Biometrics       Date:  1993-03       Impact factor: 2.571

9.  A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments.

Authors:  S G Machado; G A Robinson
Journal:  Stat Med       Date:  1994-11-30       Impact factor: 2.373

10.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984
View more
  4 in total

1.  CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.

Authors:  Licai Huang; Jing Wang; Bingliang Fang; Funda Meric-Bernstam; Jack A Roth; Min Jin Ha
Journal:  Sci Rep       Date:  2022-07-29       Impact factor: 4.996

2.  Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2013-03-07       Impact factor: 1.894

3.  Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors.

Authors:  Riki Cho; Yu Sakurai; Haleigh Sakura Jones; Hidetaka Akita; Akihiro Hisaka; Hiroto Hatakeyama
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

4.  CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.

Authors:  Francesca Zammarchi; Karin Havenith; Francois Bertelli; Balakumar Vijayakrishnan; Simon Chivers; Patrick H van Berkel
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.